While U.S. stocks faced a broadly dim session on Thursday, with the S&P 500 sliding more than 1%, shares of Bristol Myers Squibb (BMY) shone as a rare bright spot, jumping over 3%. The immediate catalyst for this strong momentum was the company’s latest quarterly and annual earnings report.
For the fourth quarter of 2025, the pharmaceutical giant reported revenue of $12.5 billion, a 1% year-over-year increase. Behind this modest growth lies the standout performance of its “new product portfolio,” which saw revenue surge 15% to $7.4 billion, acting as the core engine driving results.
Although the company’s non-GAAP net profit fell to $2.6 billion ($1.26 per share), this figure handily beat pessimistic market expectations. Analysts had, on average, forecast adjusted earnings per share of just $1.12 and revenue slightly above $12.2 billion. Bristol Myers Squibb exceeded expectations on both the top and bottom lines.
Investors were further encouraged by the company’s upbeat outlook for fiscal 2026. Management projected full-year revenue between $46 billion and $47.5 billion, with adjusted earnings per share expected to be in the range of $6.05 to $6.35. This guidance also topped the average analyst consensus.
Beyond the solid financials, a strategic collaboration announced by the company captured market attention. Bristol Myers Squibb recently revealed a partnership with tech giant Microsoft to jointly develop an AI-powered workflow. The collaboration aims to combine Microsoft’s imaging technology, widely used in U.S. healthcare institutions, with Bristol Myers Squibb’s expertise in oncology and drug development. The goal is to enable earlier diagnosis of lung cancer and a clearer path to treatment.
While the current scale of the project is limited, it showcases the vast potential of AI in diagnosing and treating major diseases, adding significant long-term growth potential to the company’s narrative.
Bristol Myers Squibb’s market-beating rise today was well-founded. It was driven by a combination of strong short-term performance from its core new drug business and a long-term strategic vision showcased through its AI healthcare partnership, which together boosted market confidence. Despite declining revenue from its legacy product portfolio, the market is currently placing greater value on the potential the drugmaker has demonstrated on its new growth trajectory.
